Search PubMed⌕ Search

Biomedical subjects

M A Medinsky

Publications and source records attributed to M A Medinsky.

At least 55 records · Page 3Linked to original sources

Acute methanol toxicity in minipigs.

The pig has been proposed as a potential animal model for methanol-induced neuro-ocular toxicosis in humans because of its low liver tetrahydrofolate levels and slower rate of formate metabolism compared to those of humans. To examine the validity of this animal model, 12 4-month-old female minipigs (minipig YU) were given a single oral dose of water or methanol at 1.0, 2.5, or 5.0 g/kg body wt by gavage (n = 3 pigs/dose). Dose-dependent signs of acute methanol intoxication, which included mild CNS depression, tremors, ataxia, and recumbency, developed within 0.5 to 2.0 hr, and resolved by 52 hr. Average maximum methanol concentrations in plasma, of 3100 +/- 700 (SD), 6200 +/- 2300, and 15,200 +/- 900 micrograms/ml were reached within 0.5 to 4 hr following methanol administration in animals given 1.0, 2.5, or 5.0 g methanol/kg, respectively. The mean initial elimination half-lives of methanol were 9.0 +/- 1.6, 22.4 +/- 6.1, and 18.9 +/- 4.3 hr, for 1, 2.5, and 5.0 g/kg doses, respectively. In 3 minipigs, a transient increase in plasma formate concentration (1.74-3.40 mEq/liter vs control = 0.5 +/- 0.3 mEq/liter) occurred 4 to 30 hr following methanol administration. Methanol- and formate-dosed pigs did not develop optic nerve lesions, toxicologically significant formate accumulation, or metabolic acidosis. Based on results following a single dose, female minipigs do not appear to be overtly sensitive to methanol and thus may not be a suitable animal model for acute methanol-induced neuro-ocular toxicosis.

Animals↗

Benzene and phenol metabolism by mouse and rat liver microsomes.

Benzene, an important industrial solvent and constituent of unleaded gasoline, causes leukemia and aplastic anemia in humans. Mice are more sensitive than rats to benzene toxicity, though neither species has been shown to respond consistently with benzene-induced leukemia. Benzene biotransformation in liver to phenol, hydroquinone, catechol and/or muconaldehyde is thought to be necessary for its hematotoxicity and/or genotoxicity. Our goal is to develop a mathematical simulation model capable of describing the pathways and kinetics of benzene metabolism by rat and mouse liver microsomes and to assess the role of species metabolic differences in species sensitivity. Microsomes were incubated with 4 microM [U-14C]-benzene or 4 microM [U-14C]phenol. Metabolite production was quantified by extraction into ethyl acetate, HPLC separation and liquid scintillation spectroscopy. After 45 min, mouse liver microsomes converted 20% of the benzene to phenol, 31% to hydroquinone and 2% to catechol. Rat liver microsomes converted 23% of benzene to phenol, 8% to hydroquinone and 0.5% to catechol. Production of hydroquinone and catechol continued for 90 min for mouse liver microsomes, while production by rat liver microsomes had virtually ceased by 90 min. Muconic acid production by mouse liver microsomes was < 0.2% and < 0.04% from benzene and phenol respectively after 90 min. A quantitative simulation model was constructed to describe the in vitro metabolism of benzene, incorporating the reaction sequences: benzene-->phenol-->catechol-->trihydroxybenzene and phenol-->hydroquinone-->trihydroxybenzene. In the model, all of the reaction steps are assumed to be catalyzed by the same enzyme(s), cytochrome(s) P450, and benzene, phenol, hydroquinone and catechol in solution are all assumed to compete, through reversible binding, for the same reaction site(s) on cytochrome(s) P450. The simulation model accurately described both the benzene and phenol kinetic data, supporting this proposed mechanism. In particular, this model suggests that the observed inhibition of benzene on phenol metabolism, and of phenol on benzene metabolism, occurs through competition for a common reaction site, which can also bind catechol and hydroquinone.

Animals↗

Research strategy for assessing target tissue dosimetry of 1,3-butadiene in laboratory animals and humans.

1,3-Butadiene is carcinogenic to rats and mice, although mice are more sensitive than rats. It is not known if butadiene poses a carcinogenic risk to humans. Butadiene requires metabolic activation to reactive epoxides that can bind to DNA to initiate a series of events that lead to tumour formation. Species differences in activation and detoxification must be considered in estimating human risks from exposure to butadiene. A research strategy for assessing the role of metabolic factors in the carcinogenicity of butadiene involves studies in laboratory animals in vivo, supplemented with studies in vitro with tissues from both laboratory animals and humans. In experiments conducted on liver and lung tissues from Sprague-Dawley rats, B6C3F1 mice and humans, we characterized the oxidation of butadiene and butadiene monoepoxide by cytochrome P450-dependent mono-oxygenases and the detoxification of butadiene monoepoxide by epoxide hydrolases and glutathione transferases. B6C3F1 mouse liver microsomes displayed a capacity for butadiene oxidation exceeding that seen in either human or rat liver microsomes. Except in mice, oxidation of butadiene occurred at rates significantly lower with lung than with liver microsomes. In general, human liver microsomes hydrolysed butadiene monoepoxide at higher rates than either rats or mice. The capacity for glutathione conjugation with butadiene monoepoxide was higher in mice than in humans or rats. The ratios of butadiene activation (P450):detoxication (hydrolysis and conjugation) are markedly different in mouse (74:1), rat (6:1) and human (6:1) liver tissues. The differences in the ratios between mice and rats are consistent with the higher carcinogenic sensitivity of mice than rats to butadiene. Factors in addition to metabolism, however, probably play a role in the carcinogenicity of butadiene in rats and mice. Metabolic rate constants for butadiene and butadiene monoepoxide oxidation and for butadiene monoepoxide hydrolysis and conjugation with glutathione, determined from physiological pharmacokinetic model simulations of butadiene-exposed rats and mice, were for the most part similar to the constants determined in vitro. The same trends that were noted in vitro were seen in vivo. The physiological dosimetry model for butadiene that includes in-vitro vitro metabolic constants can stimulate behaviour in vivo and can be used to predict blood and tissue concentrations of butadiene and its monoepoxide.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗

Effect of exposure concentration on the disposition of inhaled butoxyethanol by F344 rats.

The glycol ethers are a class of solvents widely used due to their range of vapor pressures and miscibility in aqueous and organic media. Butoxyethanol (BE) causes anemia and lowered hematocrits in rats due to direct hemolysis of red blood cells. Exposure to BE is most likely to occur by dermal contact or by inhalation. In this paper, we report the uptake, metabolism, and excretion of BE following 6-hr exposure at different inhaled concentrations. The uptake and metabolism of BE were essentially linear up to 438 ppm. The majority of the inhaled butoxy-[14C]ethanol was eliminated in the urine with butoxyacetic acid (BAA) being the major urinary metabolite, accompanied by lesser amounts of ethylene glycol and BE glucuronide. A small proportion (5-8%) of the retained BE was exhaled as 14CO2. Most (greater than 80%) of the [14C]BE-derived material in blood was in the plasma. BAA was the major metabolite of BE in plasma. Ratios of ethylene glycol to BAA in plasma were higher than those in urine. The BE-derived 14C in plasma rapidly became associated with the acid-precipitable (protein) fraction, probably due to binding of metabolites to proteins or incorporation of the BE metabolites into the carbon pool. These results indicate that, in rats, overall metabolism of BE to BAA, the hemolytic metabolite, was linearly related to the exposure concentration up to a concentration that caused severe toxicity (438 ppm). Assuming that the toxicity of inhaled BE is directly proportional to the formation of BAA, the toxicity of inhaled BE can be expected to be linearly related to the exposure concentration up to exposure concentrations that cause mortality.

Administration, Inhalation↗

Effect of dose on the disposition of methoxyethanol, ethoxyethanol, and butoxyethanol administered dermally to male F344/N rats.

The glycol ethers methoxyethanol (ME), ethoxyethanol (EE), and butoxyethanol (BE) are widely used in industrial and household products. Rodent studies indicate the ME and EE are potentially toxic compounds causing teratogenic, fetotoxic, hematotoxic, and testicular effects. Exposure of rodents to high concentrations of BE resulted in anemia due to hemolysis of blood cells, leukopenia, hemoglobinuria, and liver and kidney damage. The purpose of this study was to determine the uptake, metabolism, and excretion of dermally administered glycol ethers as a function of the externally applied dose. Three different amounts of the 14C-labeled glycol ethers (450-4000 mumole/kg) were applied to same-sized areas on the clipped backs of F344/N rats, and nonoccluded percutaneous absorption was measured. The rates of excretion of the 14C-labeled parent compound and metabolites by different routes were measured, as well as the amount of 14C remaining in the carcass. Within the dose range studied, the absorption and metabolism of these three glycol ethers by F344/N rats was linearly related to the dermally applied dose. The absorption of all three glycol ethers was approximately 20-25%, regardless of the chain length of the alkyl group or the dose administered. The majority of the absorbed dose was excreted in the urine. Feces and exhaled CO2 represented minor routes of excretion. The alkoxyacetic acid was a major metabolite for all three glycol ethers. The formation of small amounts of ethylene glycol indicated cleavage of the ether bond.(ABSTRACT TRUNCATED AT 250 WORDS)

Administration, Cutaneous↗

Benzene dosimetry in experimental animals: relevance for risk assessment.

The findings of the studies summarized in this report provide some understanding of the possible role of dosimetry in the different response of the rats and mice to benzene in the long-term bioassay studies. The more sensitive species, the mice, definitely has a higher capacity to metabolize benzene and to metabolize it to more of the putative toxic metabolites than do rats. A major finding of these studies is that in three different animal species, from mice to monkeys, the metabolic pathways leading to production of the putative toxic metabolites appear to be low-capacity, high-affinity pathways that are saturated at relatively low-exposure concentrations. This does not prove, but suggests, that the same may be true in humans. If the total formation of the putative toxic metabolites is predictive of the toxicity of benzene, then the animal studies suggest that calculations of the risk associated with low dose exposures based on the results of animal studies conducted at high doses would underestimate the toxicity of benzene. The current report concerns only dosimetry. Another problem in assessing the risk to humans from benzene exposure is the fact that the animal models do not respond to benzene in the same way as humans. The major concern for humans exposed to benzene, based on epidemiology studies, is the risk of developing acute myelogenous leukemia (Rinksy, 1987). The cancers developed by the rodents on the long-term bioassay studies were at other sites (liver, lung, Zymbal's gland, lymph tissue, ovaries, and mammary gland). There is as yet no good animal model for benzene-induced leukemia. However, it has been suggested that benzene may also increase the incidence of Hodgkin's disease, malignant lymphoma, multiple myeloma and lung cancer in humans, although a statistical basis for this is lacking (Askoy, 1985). It is not unreasonable to assume that whatever form of cancer is induced, the induction is most likely through the reactive metabolites produced from benzene. Therefore, the dosimetry of these metabolites is pertinent. Our studies indicate that benzene metabolite dosimetry data obtained in animals provides data relevant to the estimation of human risks.

Administration, Inhalation↗

Particle-associated polycyclic aromatic hydrocarbons--a reappraisal of their possible role in pulmonary carcinogenesis.

According to the model presented here, large aggregates of inert dust forming in the lung can drastically increase retention of polycyclic aromatic hydrocarbons (PAHs) that are either adsorbed or precipitated onto the dust particles. Experiments designed to demonstrate the carcinogenicity of PAHs in animals require that large amounts of PAHs be administered to induce lung cancer. If the PAHs are attached to an inert carrier dust before instillation, aggregation of particles is a very significant factor in the retention of PAHs in the lung. A slow release of particle-associated PAHs would result in a prolonged exposure to surrounding tissues from a limited number of administrations. Because an increased incidence of tumors has been observed following these types of exposures, it has been concluded that the increased retention of PAHs due to their association with inert particles is an important factor in PAH-induced pulmonary carcinogenesis. However, large aggregates of inert dust containing crystalline PAHs are unlikely to form with the much lower doses typical of human exposures. Inhaled particles are more likely to deposit and react with the surrounding lung medium without interference from other particles. Our model demonstrates that, under more typical, low-dose exposure conditions, particle-associated PAHs will be released rapidly from the particles. Sustained exposure of target tissues to PAHs will result from repeated exposures, not from increased retention due to association of PAHs with their carrier particles. This distinction is very important, because in high-dose, instillation experiments in animals, critical doses to cells, and thus tumors, should occur at the sites at which particles are retained; whereas, the much lower, but more frequent exposures common for humans should instead lead to tumors at the sites at which particles are initially deposited, but not necessarily retained.

Animals↗

Disposition of inhaled isoprene in B6C3F1 mice.

Isoprene (2-methyl-1,3-butadiene) is the monomeric unit of widely occurring natural products called terpenes. Isoprene is widely used in industry with nearly 1.1 million pounds produced in the United States in 1987. The purpose of this investigation was to determine the toxicokinetics of inhaled isoprene in B6C3F1 mice and to compare the data to previously published toxicokinetic data in F344 rats (A. R. Dahl, L. S. Birnbaum, J. A. Bond, P. G. Gervasi, and R. F. Henderson, 1987. Toxicol. Appl. Pharmacol. 89, 237-248). The comparative toxicokinetics in the two species will be useful for extrapolation of rodent toxicity data to humans. Male B6C3F1 mice were exposed to nominal concentrations of 20, 200, and 2000 ppm isoprene or [14C]isoprene for up to 6 hr. For all exposures, steady-state levels of isoprene were reached rapidly (i.e., within 15 to 30 min) after the onset of exposure. The mean (+/- SE) steady-state blood levels of isoprene (identified by headspace analysis) for the 20, 200, and 2000 ppm exposures were 24.8 +/- 3.3, 830 +/- 51, and 6800 +/- 400 ng isoprene/ml blood, respectively. At the two higher exposure concentrations, the increases in blood levels of isoprene were proportional to the increases in air concentrations of isoprene. There was approximately a 2.3-fold decrease in the retained 14C/inhaled 14C ratio with increasing exposure concentration. Depending on the exposure concentration, from 52% (20 ppm isoprene) to 73% (2000 ppm isoprene) of the metabolite-associated (nonisoprene) radioactivity was excreted in the urine over a 64-hr postexposure period. 14CO2 exhalation after the end of the 6-hr exposure was minimal (2%) at the 20 ppm exposure and increased up to 18% at the higher isoprene exposure concentrations. These data suggest that metabolism of isoprene in mice is nonlinear within the range of exposure concentrations used in this study. Hemoglobin adduct formation reached near-maximum between 200 and 2000 ppm isoprene exposure concentration, consistent with our conclusion that pathways for metabolism of isoprene were saturated. Isoprene metabolites were present in blood after inhalation of isoprene at all concentrations studied. There were substantial differences in the toxicokinetics of inhaled isoprene in mice compared to rats. In mice, fractional retention of inhaled isoprene, which reflects, in part, metabolism of isoprene, was linearly related to exposure concentrations up to 200 ppm but decreased at 2000 ppm; in rats, fractional retention of inhaled isoprene decreased with increasing exposure concentration over a range of exposures from 8 to 1500 ppm.(ABSTRACT TRUNCATED AT 400 WORDS)

Absorption↗

The retention of polycyclic aromatic hydrocarbons in the bronchial airways and in the alveolar region--a theoretical comparison.

Several experiments indicate that physical transport phenomena such as molecular diffusion and partitioning between aqueous and lipid phases have a profound influence on the pulmonary retention of polycyclic aromatic hydrocarbons (PAHs). Because the average distance of diffusion between the air interface and the capillary blood is only about 0.5 microm in the alveoli, whereas in the bronchi it probably exceeds 50 microm, there should be a fundamental difference between the bronchial airways and the alveolar region in the retention of PAHs. A theoretical model was developed to simulate the retention of lipophilic substances in the two regions of the lung. Results show that a substance like benzo[a]pyrene, a PAH, may be retained for hours in the bronchi, compared to less than 1 min in the alveoli. This predicted dramatic difference in retention could explain the characteristic, biphasic pattern in the pulmonary clearance of PAHs observed in many animal experiments, but more importantly, it could also explain the fact that human lung cancers occur predominantly in the bronchi, although only a small fraction of inhaled particles carrying PAHs are deposited there.

Animals↗

In vivo deposition of ultrafine aerosols in the nasal airway of the rat.

We studied the deposition of ultrafine aerosols, ranging in geometric diameter from 0.005 to 0.1 microns, in the nasal airway of Fischer-344/N rats, at inspiratory flow rates of 200, 300, 400, and 600 ml/min. Simultaneously, we measured the pressure drop across the rat nasal airway. The purpose was to determine whether the in vivo deposition of ultrafine aerosols in the rat nasal airway is the same as the deposition observed in rat nasal casts. At a flow rate of 400 ml/min, corresponding to the normal mean inspiratory flow rate of the rat, deposition efficiency increased from 6 to 58%, when the particle diameter decreased from 0.1 to 0.005 microns. For 0.005-microns-diameter particles, the deposition efficiency decreased from 68 to 52% when the flow rate was increased from 200 to 600 ml/min. These results agree well with those from previous experiments with nasal casts, which indicated that diffusion is the dominant mechanism for deposition of ultrafine aerosols. The pressure drop in the nasal airway of the rat increased almost linearly with flow rate, from 73 Pa at 200 ml/min to 247 Pa at 600 ml/min. These values are within the range of those obtained in previous experiments with nasal casts, although the pressure drop in casts increased as a power greater than 1 with flow rate. The results of our study support the use of nasal airway casts to estimate the in vivo deposition of ultrafine aerosols.

Aerosols↗

Measurement of steady-state blood concentrations in B6C3F1 mice exposed by inhalation to vinylidene fluoride.

The purpose of this study was to obtain data on blood concentrations of vinylidene fluoride (VDF), an important plastics monomer in B6C3F1 mice during inhalation exposure. A new method for sampling blood from mice during the exposures was developed. The technique used a pernasal exposure tube with an outer, sliding cylinder that allowed access to the heart through the thorax. Blood was removed from an anesthetized mouse via heart-puncture while the animal was being exposed to VDF. Concentrations of VDF were measured in blood of mice during 6-h exposures to nominal concentrations of 250, 3750, or 15,000 ppm VDF. A physiological model developed to simulate blood levels of VDF in rats was adapted for mice by incorporating physiologically realistic parameters for mice where appropriate (alveolar ventilation, cardiac output, blood flow to organs, and organ volumes) and by assuming that chemical-specific parameters such as tissue/blood partition coefficients determined for rats could also be applied to mice. Measured steady-state levels of VDF in blood of mice increased with increasing exposure concentration. For both the 15,000 and 3750 ppm VDF exposures, the experimentally determined data fell within the 95% confidence interval predicted by the physiological model. For the 250 ppm VDF exposure, the experimentally determined values for VDF in blood were lower than what was predicted by the model. Model predictions indicated that for mice, as observed for rats, levels of VDF would rise very rapidly, reaching steady-state within minutes of exposure, and that at the end of exposure, blood levels will decline rapidly. At the two lowest exposure concentrations, we were unable to detect VDF in blood taken 15 min or longer after cessation of exposure, suggesting that the post-exposure levels were at or below our limit of detection which was 4 ng VDF/ml blood. For the 15,000 ppm exposure VDF could be detected in blood up to 15 min post exposure.

Administration, Inhalation↗

Disposition of three glycol ethers administered in drinking water to male F344/N rats.

The glycol ethers 2-methoxyethanol (ME), 2-ethoxyethanol (EE), and 2-butoxyethanol (BE) are widely used solvents in industrial and consumer applications. The reproductive, teratogenic, and hematotoxic effects of the glycol ethers are due to the alkoxyacetic acid metabolites of these compounds. The effect of alkyl group length on disposition of these three glycol ethers was studied in male F344/N rats allowed access for 24 hr to 2-butoxy[U-14C]ethanol, 2-ethoxy[U-14C]ethanol, or 2-methoxy[U-14C]ethanol in drinking water at three doses (180 to 2590 ppm), resulting in absorbed doses ranging from 100 to 1450 mumols/kg body wt. Elimination of radioactivity was monitored for 72 hr. The majority of the 14C was excreted in urine or exhaled as CO2. Less than 5% of the dose was exhaled as unmetabolized glycol ether. Distinct differences in the metabolism of the glycol ethers as a function of alkyl chain length were noted. For BE 50-60% of the dose was eliminated in the urine as butoxyacetic acid and 8-10% as CO2; for EE 25-40% was eliminated as ethoxyacetic acid and 20% as CO2; for ME 34% was eliminated as methoxyacetic acid and 10-30% as CO2. Ethylene glycol, a previously unreported metabolite of these glycol ethers, was excreted in urine, representing approximately 10, 18, and 21% of the dose for BE, EE, and ME, respectively. Thus, for longer alkyl chain lengths, a smaller fraction of the administered glycol ether was metabolized to ethylene glycol and CO2. Formation of ethylene glycol suggests that dealkylation of the glycol ethers occurs prior to oxidation to alkoxyacetic acid and, as such, represents an alternate pathway in the metabolism of these compounds that does not involve formation of the toxic acid metabolite.

Alcohol Dehydrogenase↗

Benzene hemoglobin adducts in mice and rats: characterization of formation and physiological modeling.

Benzene is a myelotoxin and a human leukemogen. Humans are exposed to this compound, both occupationally and environmentally. This study was conducted to determine whether formation of benzene-derived adducts with blood hemoglobin (Hb) can be used as a biomarker of exposure to benzene. B6C3F1 mice and F344/N rats were given 0.1 to 10,000 mumol [14C]benzene/kg body wt, orally. Twenty-four hours later, animals were euthanized, and globin was isolated from blood samples. The globin was analyzed by liquid scintillation spectrometry for the presence of [14C]benzene-derived adducts. Hb adduct formation was linear with respect to dose for amounts of up to 500 mumol [14C]benzene/kg body wt, for both rodent species. Within this linear dose-response range, mice formed adducts from [14C]benzene approximately 3.5 times less efficiently [0.022 +/- 0.010 (pmol adducts/mg globin)/(mumol/kg body wt dose)] than did rats [0.076 +/- 0.014 (pmol adducts)/(mumol/kg body wt dose)]. Benzene-derived Hb adducts also accumulated linearly when mice and rats were given up to three daily doses of 500 mumol [14C]benzene/kg body wt. These data were used to develop a physiological model for benzene-derived Hb adduct formation. Both first-order and saturable pathways for adduct formation were incorporated. The results showed that the model simulated the levels of Hb adducts in both mice and rats after oral exposures to benzene and predicted the levels of Hb adducts present after inhalation exposure. These studies suggest that Hb adducts might be useful biomarkers for human exposures to benzene.

Animals↗

Effect of inhaled azodicarbonamide on F344/N rats and B6C3F1 mice with 2-week and 13-week inhalation exposures.

Azodicarbonamide (ADA), a compound used in the baking and plastics industries, has been reported to cause pulmonary sensitization and dermatitis in people. Two-week repeated and 13-week subchronic inhalation exposures of F344/N rats and B6C3F1 mice to ADA were conducted to determine the toxicity of inhaled ADA. The mean air concentrations of ADA in the 2-week studies were 207, 102, 52, 9.4, or 2.0 mg/m3. No exposure-related mortality nor abnormal clinical signs were observed in rats or mice during or after exposure. The terminal body weights were slightly depressed in the highest exposure group. Liver weights were lower in male rats exposed to 200 mg ADA/m3. No significant lesions were noted on either gross or histologic evaluation of rats or mice. In the 13-week subchronic study, the mean air concentrations of ADA were 204, 100, or 50 mg/m3. No mortality or clinical signs related to exposure were observed. The terminal body weights of exposed rats were not significantly different from those of control rats but were significantly depressed in mice exposed to 100 or 200 mg ADA/m3. No histopathological lesions were noted in mice. Lung weights were increased and enlarged mediastinal and/or tracheobronchial lymph nodes were noted in rats exposed to 50 mg ADA/m3. No exposure-related lesions were observed microscopically in rats exposed to 100 or 200 mg ADA/m3. All rats in the 50 mg ADA/m3 exposure group only had lung lesions that consisted of perivascular cuffing with lymphocytes and a multifocal type II cell hyperplasia, suggesting a possible immune reaction to an antigen in the lung. Viral titers for rats exposed to 50 mg ADA/m3 were negative for Sendai virus and pneumonia virus of mice, which produce similar lesions. The possibility of an unknown viral antigen causing this lesion cannot be eliminated. Lung tissue from male rats was analyzed for ADA and biurea, the major metabolite of ADA. No ADA was detected. The amount of biurea in the lungs increased nonlinearly with increasing exposure concentration, suggesting that clearance was somewhat impaired with repeated exposures. However, even at the highest exposure concentration, this amount of biurea was less than 1% of the estimated total ADA deposited over the exposure period. In summary, ADA is rapidly cleared from the lungs, even when inhaled at concentrations up to 200 mg/m3. Exposure to ADA for up to 13 weeks did not appear to be toxic to rodents.

Administration, Inhalation↗

A physiological model for simulation of benzene metabolism by rats and mice.

Studies conducted by the National Toxicology Program on the chronic toxicity of benzene indicated that B6C3F1 mice are more sensitive to the toxic effects of benzene than are F344 rats. A physiological model was developed to describe the uptake and metabolism of benzene in rats and mice and to determine if the observed differences in toxic effects could be explained by differences in the pathways for metabolism of benzene or by differences in uptake of benzene. Major pathways for elimination of benzene included metabolism to hydroquinone glucuronide or hydroquinone sulfate, phenyl glucuronide or phenyl sulfate, muconic acid, and prephenyl mercapturic acid or phenyl mercapturic acid. Model simulations for total benzene metabolized and for profiles of benzene metabolites were conducted for oral or inhalation exposure and compared to data for urinary excretion of benzene metabolites after exposure of rats and mice to [14C]- or [3H]-benzene by inhalation or gavage. Results for total amount of benzene metabolized, expressed per kilogram body weight, indicated that for inhalation exposure concentrations up to 1000 ppm, mice metabolized at least two to three times as much benzene as did rats. Simulations of oral exposure to benzene resulted in more benzene metabolized per kilogram body weight by rats at oral exposures of greater than 50 mg/kg. Patterns of metabolites formed after either route of exposure were very different for F344/N rats and B6C3F1 mice. Rats primarily formed the detoxification metabolite, phenyl sulfate. Mice formed hydroquinone glucuronide and muconic acid in addition to phenyl sulfate. Hydroquinone and muconic acid are associated with pathways leading to the formation of the putative toxic metabolites of benzene. Metabolic rate parameters, Vmax and Km, were very different for hydroquinone conjugate and muconic acid formation compared to formation of phenyl conjugates and phenyl mercapturic acids. Putative toxication pathways could be characterized as high affinity, low capacity whereas detoxification pathways were low affinity, high capacity. Model simulations suggested that for both rats and mice at lower exposure concentrations hydroquinone and muconic acid represented a larger fraction of the total benzene metabolized than at higher exposure concentrations where detoxification metabolites were predominant. Preferential production of a putative toxic metabolite at low exposure concentrations may have important implications in risk assessment for benzene.

Administration, Inhalation↗

Effect of four-week repeated inhalation exposure to unconjugated azodicarbonamide on specific and non-specific airway sensitivity of the guinea pig.

Reports of respiratory problems among industrial workers exposed repeatedly by inhalation to azodicarbonamide (ADA) raised concern that ADA might be a pulmonary sensitizer. We used a non-invasive method for measuring specific airway conductance to evaluate the potential for repeated inhalation of unconjugated ADA to cause specific or non-specific pulmonary sensitization in the guinea pig. Two groups of male Hartley guinea pigs were exposed 6 h/day, 5 days/week for 4 weeks to aerosolized ADA at 51 or 200 mg/m3, or to filtered air as controls. One group was tested for specific sensitization to ADA by measuring specific airway conductance during inhalation challenge with ADA before and on the third day after the 4-week ADA exposure. The ADA concentrations for the challenges were identical to the repeated exposure concentrations (51 or 200 mg/m3, 200 mg/m3 for controls). The other group was tested for non-specific airway sensitization by inhalation challenge with aerosolized histamine before and after the 4-week ADA exposure. Histamine was administered in stepwise increasing concentrations to elicit an airway response in each guinea pig. Skin tests for immunological responses to ADA, body weight and histopathology of the respiratory tract and skin test sites were also evaluated. The 4-week exposure to ADA did not result in either specific or non-specific airway sensitization. The ADA exposure did not induce positive skin reactions, influence body weight or cause histopathological responses. These results indicate that ADA, acting alone (i.e. not conjugated to a protein), is not a pulmonary sensitizer in the guinea pig exposed repeatedly for 4 weeks and challenged to simulate a 'Monday morning' exposure.

Administration, Inhalation↗

A toxikinetic model for simulation of benzene metabolism.

People exposed to benzene, an important industrial solvent and a common pollutant, can develop aplastic anemia and leukemia. The objectives of this study were to develop a physiological model for the metabolism of benzene, based on studies in laboratory animals, and to use this model to predict benzene metabolism in people to concentrations near the current permissible exposure limits. Model simulations predicted that for 8-h inhalation exposures to below 10 ppm, hydroquinone metabolites would predominate. Hydroquinone is associated with pathways leading to the formation of the putative toxic metabolite, benzoquinone. Lower levels of muconic acid, a marker for the putative toxic metabolite, muconaldehyde, were predicted. At concentrations above 10 ppm, detoxification metabolites such as the phenyl conjugates predominate. Predictions of benzene metabolism in humans based on our physiological model may have important implications for risk assessment. Because there may be preferential production of a putative toxic metabolite at low exposure concentrations, linear extrapolation of toxicity observed at high concentrations may underestimate risk at low exposure concentrations.

Animals↗